On November 13th, the Associated Press released an article showing mixed reviews of Arcoxia, the cox-2 inhibitor drug that Merck is hoping to market as a replacement for its drug Vioxx. Merck pulled Vioxx off the market in late 2004 because of studies showing an increased risk of heart attack / cardiovascular events when taking the drug. The results of 3 studies were due to be published this week in the British journal called the Lancet and also presented at an American Heart Association conference. The studies, sponsored by Merck, compare Arcoxia to diclofenac. Diclofenac is sold in the U.S. by Novaris AG as both Cataflam and Voltaren. Merck is hoping that the studies will help persuade the FDA to give approval for Arcoxia in the U.S. Arcoxia has been approved for use in other countries for several years. Merck pooled the results of the 3 studies. In total there were more than 34,000 arthritis patients, with an average age of 63, in the U.S. and 37 other countries. One third had heart ...
Generic Name: NAPROXEN ENTERIC-COATED TABLET - ORAL Pronounced: (nah-PROX-en) Naproxen Oral Interactions
Drug interactions may change how your medications work or
increase your risk for serious side effects. This document does not contain all
possible drug interactions. Keep a list of all the products you use (including
prescription/nonprescription drugs and herbal products) and share it with your
doctor and pharmacist. Do not start, stop, or change the dosage of any
medicines without your doctor's approval.
Products that may interact with this drug
high blood pressure drugs (including ACE inhibitors such as
captopril, lisinopril and angiotensin II receptor blockers such as losartan,
This medication may increase the risk of bleeding when
taken with other drugs that also may cause bleeding. Some affected drugs
include anti-platelet drugs such as clopidogrel, "blood thinners" such as
On Thursday, April 12 an FDA advisory panel will discuss
whether or not to recommend that the FDA approve Merck & Co’s COX-2
inhibitor, Arcoxia (etoricoxib). The drug is manufactured by Merck, the
same company that made Vioxx, which was pulled from the market in the fall of
2004. Merck applied for approval to sell Arcoxia as a treatment for the
signs and symptoms of osteoarthritis .
Currently, the only COX-2 inhibitor remaining on the market
is Celebrex , made by Pfizer, Inc. These COX-2 inhibitors are all types of
NSAIDs. Over the counter types of NSAIDs include naproxen (sold as Aleve)
and ibuprofen. The difference between the prescription COX-2s and the OTC
NSAIDS (and the big selling point) is that the COX-2s have a lower risk of
bleeding ulcers and other GI complications than other NSAIDs. However,
studies have shown that the COX-2s have a higher risk of heart attack and
strokes. Vioxx and Bextra were both subsequently...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.